Stock Events

Stock Events

Altimmune 

$3.17
311
+$0.1+3.43% Today

Statistics

Day High
3.26
Day Low
3.04
52W High
7.71
52W Low
2.6
Volume
82,963,408
Avg. Volume
-
Mkt Cap
329.96M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Jan 17
$87.3
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

7MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.36
-0.31
-0.26
-0.21
Expected EPS
-0.240045
Actual EPS
N/A

Financials

-475,295%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
40,000Revenue
-190.12MNet Income

Analyst Ratings

19Average Price Target
The highest estimate is 25.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ALT. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novavax
NVAX
Mkt Cap1.32B
Novavax is a direct competitor in the development of vaccines for infectious diseases, similar to Altimmune's focus area.
Moderna
MRNA
Mkt Cap17.99B
Moderna is involved in mRNA-based vaccines and therapeutics, competing in the same innovative vaccine technology space as Altimmune.
BioNTech
BNTX
Mkt Cap24.67B
BioNTech competes with Altimmune in the development of vaccines, including their work on COVID-19 vaccines.
Pfizer
PFE
Mkt Cap149.77B
Pfizer, through its partnership with BioNTech and other vaccine initiatives, is a major competitor in the vaccine market.
Johnson & Johnson
JNJ
Mkt Cap546.9B
Johnson & Johnson, with its global reach and vaccine development, competes in the same space as Altimmune.
Inovio Pharmaceuticals
INO
Mkt Cap89.75M
Inovio Pharmaceuticals is focused on DNA medicines, including vaccines, making it a competitor in the innovative vaccine development space.
GSK
GSK
Mkt Cap103.01B
GlaxoSmithKline, with its extensive vaccine portfolio, is a significant competitor in the global vaccine market.
Sanofi
SNY
Mkt Cap110.4B
Sanofi is involved in vaccine development and distribution, making it a competitor in the global vaccine and immunotherapy market.

About

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Show more...
CEO
Mr. Jerome Benedict Durso
Employees
59
Country
United States
ISIN
US02155H2004

Listings

STU
DE
3G0.STU
F
DE
3G0.F
MU
DE
3G0.MU
MX
MX
ALT1.MX

0 Comments

Share your thoughts

FAQ

What is Altimmune stock price today?▼
The current price of ALT is $3.17 USD — it has increased by +3.43% in the past 24 hours. Watch Altimmune stock price performance more closely on the chart.
What is Altimmune stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Altimmune stocks are traded under the ticker ALT.
Is Altimmune stock price growing?▼
ALT stock has risen by +21.29% compared to the previous week, the month change is a -4.2% fall, over the last year Altimmune has showed a -36.58% decrease.
What is Altimmune market cap?▼
Today Altimmune has the market capitalization of 329.96M
When is the next Altimmune earnings date?▼
Altimmune is going to release the next earnings report on May 07, 2026.
What were Altimmune earnings last quarter?▼
ALT earnings for the last quarter are -0.27 USD per share, whereas the estimation was -0.23 USD resulting in a -15.38% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Altimmune revenue for the last year?▼
Altimmune revenue for the last year amounts to 40,000 USD.
What is Altimmune net income for the last year?▼
ALT net income for the last year is -190.12M USD.
Does Altimmune pay dividends?▼
Yes, ALT dividends are paid en. The last dividend per share was 87.3 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Altimmune have?▼
As of May 06, 2026, the company has 59 employees.
In which sector is Altimmune located?▼
Altimmune operates in the Health & Wellness sector.
When did Altimmune complete a stock split?▼
The last stock split for Altimmune was on September 14, 2018 with a ratio of 1:30.
Where is Altimmune headquartered?▼
Altimmune is headquartered in Gaithersburg, United States.